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        Marek‟s disease virus (MDV) infection causes atherosclerosis, and prior 
vaccination prevented the development of this disease. Two main strategies to resist 
Marek‟s disease (MD) have been demonstrated: vaccination and genetic resistance. 
However, little is known about the role of genetic resistance in the progression of MDV 
induced atherosclerosis. Atherosclerosis is primarily associated with lipoprotein 
metabolism. The purpose of this study was to investigate whether lipoprotein 
metabolisms are different in distinct MD susceptible and resistant chicken lines. Here, we 
studied different backgrounds of lipoprotein metabolism in the two lines and the changes 
of lipoprotein levels in response to MDV infection. The results showed that during 
chicken growth, the increase in total cholesterol was mostly due to the increasing 
(LDL+VLDL) in MD susceptible line, whereas it was mainly due to the elevating HDL 
in MD resistant line. These results suggested that different lipoprotein metabolisms exist 
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Chapter 1: Literature review 
Introduction 
Atherosclerosis is a progressive disease characterized by lipid accumulation in the 
large arteries, which causes about 50% of all deaths in westernized societies
1
. It has 
been demonstrated that atherosclerosis is a complex process which involves the 
interaction of several genetic and environmental factors, including diabetes, 
hypercholesterolemia and cigarette smoking
2
. Since atherosclerotic lesions are 
thought to be initiated by injury to the vascular endothelium, considerable research 
has been focused on studying the mechanisms responsible for this initial injury
2
. 
Herpesviruses have been proposed as potential initiators of arterial injury. This 
statement was based on several studies in the late 1970‟s, which revealed that 





MDV is an oncogenic herpesvirus that causes several syndromes in the chicken. It has 
been demonstrated that MDV infection can induce occlusive atherosclerotic lesions in 
large coronary arteries and aortas of infected chickens
5
. MDV infection also affected 
enzymatic activities in arterial smooth muscle cells, which resulted in aortic lipid 
accumulation in chicken, including cholesterol, cholesterol ester, triacylglycerol and 
phospholipids
4
. It has been suggested that the lipid accretion in aortas of MDV 





Besides cholesterol metabolism, lipoprotein metabolism was involved in 
atherosclerosis
7, 8
. Progressive accumulation of cholesterol in the arterial wall causes 
atherosclerosis. Lipoproteins, as the key carriers of cholesterol through the circulating 
system, have been reported to be associated with the development of atherosclerosis. 
For instance, the low density lipoprotein (LDL) accumulated in the subendothelial 
matrix, resulting in a primary initiating event in atherosclerosis
1
. Moreover, 
epidemiologic evidence has revealed LDL cholesterol as a risk factor for 
atherosclerosis
9
. Conversely, the high density lipoprotein (HDL) is strongly 
protective against atherosclerosis. This protective effect results from the role of HDL 
in transporting excess cholesterol from foam cells to the liver, thus relieving the 




Studies for the role of lipoprotein metabolism in atherosclerosis induced by MDV 
infection will give a better understanding for the initial process of atherosclerosis. 
Furthermore, it is important to note that, besides this animal model, studies in humans 
have also reported the epidemiological association between herpesviral infections and 
accelerated atherosclerosis in heart transplant patients
11, 12
. Multiple studies about 
herpesviral induced atherosclerosis has led to the hypothesis that herpesviruses 
initiate vascular disease processes in humans
13, 14
.  Therefore, with this model of 
MDV infected chicken, elucidating the role of lipoprotein metabolism for herpesvirus 
induced atherosclerosis could enable us to demonstrate the etiology and pathogenesis 




Marek’s disease and atherosclerosis 
Marek’s disease 
Marek‟s disease (MD) was first recognized by József Marek in 1907 as a generalized 
polyneuritis in chickens. It was also shown that MD was associated with visceral 
lymphoma in the later 1920s
15,16
. The clinical disease is similar to the neoplastic 
(retrovirus-induced lymphatic leukosis) disease in chicken. A clear differentiation 
between retrovirus- and MDV-induced neoplasia was made in the later 1960s, when 
the herpesvirus aetiology of MD was identified
17
. It is important to note that in the 
1960s, the lymphoid form of MD became a serious problem with the expansion and 
intensification of poultry production. It was only two years after the identification and 
cell-culture isolation of MDV
18,19
 that the use of attenuated MDV was introduced as a 
highly effective vaccine
20,21
. The vaccines achieved unparalleled success in 
preventing the disease and provided a landmark: the first effective and widespread  
immune prophylaxis against a virus-induced cancer in any species. However, over the 
last 30 years, the virus has mutated to increasly virulent forms and vaccine breaks 
began to appear, which has led to the requirement of new strategies for controlling 
and preventing the disease. Importantly, it is well known that MD has a worldwide 
impact on the poultry industry. It has been demonstrated that MDV pathogenic strains 
are present in nearly every country from the multi-annual animal disease status report 
by the Office International des Epizooties. Furthermore, the economic impact of MD 
has been estimated to be US$ 1-2 billion annually. Therefore, investigation of MD 
has remained essential to this day. 
Marek’s disease virus (MDV) 
4 
 
MDV is an oncogenic herpesvirus that causes several syndromes in the chicken, its 
natural host. MDV was originally classified as a Gammaherpesvirus because its 
biological behavior and ability to infect lymphocytes are similar to Epstein-Barr virus 
(a γ-herpesvirus). However, electron-microscopy studies of the MDV genome found 
that MDV is a double-stranded linear DNA molecule
22
 and possesses repeat 
structures, which are characteristic of  Alphaherpesvirinae 
23
. Therefore, on the basis 
of genomic properties, MDV is currently classified as an alphaherpesvirus.  
 
The current model of MDV pathogenesis describes the disease in terms of two 
phases: the early cytolytic phase, and the latent and tumor phase of MDV infection
24
. 
In brief, the first step of MDV infection in the chicken is inhalation of the virus. 
Phagocytic cells in the respiratory route become infected
25
, and within 24 hours of 
uptake of MDV-carrier cells, several tissues become infected, including the spleen, 
thymus and the bursa of Fabricius
26
. Here, the virus meets B cells and later activates 
CD4
+
 as its main primary targets for the first phase of cytolytic replication
27,28
. After 
an early cytolytic phase, MDV enters the latent phase of infection from 6-7 days post 
infection. During MDV latency, the viral genomes present in the host cells, but there 
is no production of infectious progeny virus
29,30
. MDV latency is difficult to study 
since distinguishing latently infected cells from transformed cells is nearly 
impossible. Subsequently, there is transformation of latently infected cells to 
lymphoblastoid tumor cells
15, 31
, which is generally considered as the ultimate 
consequence of interaction of MDV with the host cells. Indeed, pathogenesis of MD 
is complex and the life cycle of this fascinating herpesvirus remains to be elucidated, 
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such as the molecular details of T-cell transformation and the factors that control 
tumor formation. 
 
Pathology of Marek’s disease 
MDV infection leads to pathological changes in its host, which involve lymphoid, 
nervous and other tissues of the chicken. The current pathology of MD is different 
from when it was first described in 1907, due to the increasing virulence of MDV. 
Currently, there are several pathological changes known to occur after MDV 
infection. 
Acute cytolytic infection 
It has been found that an acute cytolytic infection of lymphoid tissue appears at 3 
days post infection, especially in the bursa, thymus and spleen
32





 T cells are activated and infected in these organs, where the virus infection 
provokes an acute inflammatory response
27
. Moreover, the bursa and thymus exhibit 
severe regression of bursa lymphoid follicles and thymic cortex, respectfully, which 
result in weight loss in these organs
33
. However, inflammatory response in the spleen 
results in increase in weight. 
Central nervous system and peripheral neuropathy 
In 1959, Zander described a new encephalitic syndrome termed as „transient 
paralysis‟ (TP). This clinical syndrome was related to brain lesions, including acute 
vasculitis, vasogenic oedema and perivascular cuffing
34, 35
. Subsequently, two further 
syndromes of central nervous system, „persistent neurological disease‟ (PND) and 
„late paralysis‟, were identified by Gimeno in 1999
36
. Additionally, in 1967, Payne 
6 
 
and Biggs demonstrated peripheral nerve lesions, which were considered 





Multifocal lymphoid proliferation appears one week after MDV infection and visceral 
lymphomas was involved in various tissues, such as the gonads, liver, kidney, spleen, 
heart, bursa and skeletal muscles. MD lymphoma is a cytological complex, which 
consists of transformed T cells and several other cells, including B cells, macrophages 




Atherosclerosis is a complex process and involves the interaction of genetic and 
environmental factors. It has been demonstrated that injury to the vascular 
endothelium initiates the atherosclerotic lesions and herpesviruses have been 
described as potential initiators for arterial injury
5
. This theory was based on studies 
from Fabricant and colleagues in the 1970s, who found an association between 
coronary atherosclerosis and MDV infection, an avian herpesvirus. The results from 
this group were: 
(1) MDV infection induced occlusive atherosclerotic lesions in large coronary 
arteries and aortas of infected normocholesterolemic and 
hypercholesterolemic chickens. In contrast, visible atherosclerotic lesions 
were not found in uninfected normocholesterolemic and hypercholesterolemic 
chickens. Histological evaluation demonstrated that arterial changes were 





(2) At 4 and 8 months after MDV inoculation, MDV infected chickens had a 
significant increase (P<0.05) in total aortic lipid accumulation, including 
cholesterol, cholesterol ester, triacylglycerol and phospholipids, as compared 
with aortas in uninfected chickens. It has been demonstrated that the lipid 





Marek’s disease resistant and susceptible lines 
There are two main strategies for controlling MD: vaccination and genetic resistance, 
which have brought enormous benefits to the modern poultry industry
40
. However, 
aggressive increase in MD vaccinations drive MDV evolution to increased levels of 
virulence, which rendered renewed interest to study genetic selection to improve MD 
resistance. Differences in genetic resistance to MD were first investigated by 
Asmundson and Biely in 1930s
41
. These results were subsequently confirmed by 
other surveys and experiments
42, 43
. Currently, two distinct genetic resistances to MD 
have been identified: chicken major histocompatibility complex (MHC) associated 
resistance, and non-MHC associated resistance.  
 
MHC associated resistance 
It had been demonstrated that the inheritance of alleles in the B blood was associated 
with increased MD resistance
44
. Considering the B blood group locus as a marker for 
MHC, it has been indicated that genes within the MHC were responsible for MD 
8 
 
resistance. Moreover, the N and P lines were reported by Hutt and Cole in 1947
42
, and 
the differences in susceptibility between two lines were associated with their MHC
45
. 
Non-MHC associated resistance 
Besides the N and P lines, the resistant and susceptible lines (line 6 and 7) have been 
reported by Stone at East Lansing in 1975, who also provided the basis for studying 
genetic resistance. Importantly, line 6 and 7 have the same MHC haplotype
46
, which 
indicated that differences in resistance must be related with non-MHC genes. There 
are dramatic differences in the size of primary lymphoid organs between line 6 and 7  
(e.g., the larger lobes of the thymus in line 7)
47
. Furthermore, line 7 has higher 
lymphoproliferation traits than line 6 (e.g., the lymphocyte response to mitogens in 
vitro)
48
. The development of genomic mapping for chicken, together with DNA 
arrays and interference RNA (RNAi), makes it possible to identify the genes 
responsible for resistance and susceptibility to MD. Chicken genetic resistance 
possibly provides more sustainable means to prevent MD outbreaks in the future. 
 
Lipoprotein and atherosclerosis 
Cholesterol 
Lipid organization in biological membranes is crucial for cell functions. Cholesterol 
is an important structural element of cell membranes and subcellular particles in 
higher eukaryotes
49
, and acts as an essential determinant for membrane organization. 
For example, cholesterol helps to construct a barrier between cellular compartments, 
modulate the fluidity of the cell membrane, regulate the biological function of 





addition to its structural role, cholesterol is an obligatory precursor for steroid 
hormones, vitamin D, and bile acids; it is necessary for the activation of several 
neuronal signaling molecules
51, 52
. In animals, only a small amount of circulating 
cholesterol comes from the diet, and more than 80 % is derived from endogenous 
synthesis
8
. The most actively synthesizing organs are the liver and intestine, where 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyses acetyl-CoA to 
produce cholesterol. Additionally, most circulating cholesterol is esterified with long-




Since cholesterol plays an indispensible role for normal cell function, organisms have 
developed complex and sophisticated mechanisms to regulate cholesterol levels 
within a proper range
53
. Cholesterol, synthesized mainly in the liver and intestine or 
obtained from food, is delivered throughout the body to exert its biological functions. 
For long-distance transfer among cells through the aqueous environment, cholesterol 
and cholesterol ester, as hydrophobic molecules, must be shuttled by spheroidal 
macromolecules called lipoproteins. Therefore, it is not surprising that lipoprotein can 
profoundly influence cholesterol distribution or metabolism and eventually modulate 
its functions. 
 
Lipoprotein structure and classification  
Lipoproteins are the macromolecular vehicles that transport hydrophobic small 
molecules throughout the aqueous environment
54
. A lipoprotein is made up of two 
parts: a hydrophobic core and a hydrophilic coat
55, 56
. The core of a lipoprotein 
10 
 
contains apolar components, such as triacylglycerols and esterified cholesterol. The 
coat of a lipoprotein consists of a phospholipid monolayer with polar head groups 
facing the aqueous system. Several amphiphilic molecules, such as free cholesterol 
(unesterified) and apolipoproteins, embed in the phospholipid layer and confer 




Lipoproteins are assigned into four main classes according to size, particle density 
and composition: chylomicrons, very low density lipoproteins (VLDLs), low density 
lipoproteins (LDLs) and high density lipoproteins (HDLs). Chylomicrons and VLDLs 




Chylomicrons are the lowest density molecules with the largest diameter (> 75 nm), 
and primarily consist of triacylglycerols (80-88% weight by weight (w/w)) and a 




VLDLs, similar to chylomicrons, are mainly composed of triacylglycerols (about 45-
50% (w/w)) and also contain unesterified and esterified cholesterol. VLDLs have 
particle sizes ranging from 30-80 nm in diameter
54
. The main physiological role of 
VLDLs is to transport triacylglycerols from the liver to peripheral tissues for use. The 
VLDLs remnants are in part cleared by hepatic receptors, but the main fraction (70%) 
remaining in the plasma is subsequently converted to LDL through the removal of 
11 
 
triacylglycerols by lipoprotein lipase (LPL) and loss of apolipoprotein E by 




LDLs are the catabolism product of VLDLs and have particle sizes ranging from 18-
25 nm in diameter
54
. Compared with chylomicrons and VLDLs, LDLs primarily 
consist of cholesterol and cholesterol esters, and contain apolipoprotein B-100. LDLs 
serve as the primary transport mechanism to deliver cholesterol from the liver to 
peripheral tissues, and transport 70-80% of the circulating cholesterol in humans
60
. 





HDL particles are a heterogeneous mixture with the smallest diameter (< 12 nm). In 
contrast to other lipoproteins, HDLs are of relatively high protein content 
(approximately 50% (w/w)), containing primarily apolipoprotein A1 and A2
54
. In 
addition to a high protein content, HDLs are composed of unesterified cholesterol and 
triacylglycerols
62
. HDLs serve as a shuttle that transports unesterified cholesterol 
from the peripheral tissues to the liver for excretion. 
 
Lipoprotein metabolism 
Lipoprotein metabolism is a complex and sophisticated network, including assembly, 
secretion, processing and catabolism
8
. In the small intestine, dietary fats are absorbed 
and converted into triacylglycerols (TGs). TGs are packaged with cholesterol ester 
and apolipoprotein B isoform B48 to form chylomicrons. Chylomicrons are secreted 
12 
 
via the lymphatic system, and circulate in the bloodstream until they interact with 
lipoprotein lipase (LPL). LPLs rapidly hydrolyze TGs in the chylomicrons into free 
fatty acid, leading to the formation of chylomicron remnants, which are cleared by the 




In VLDL and LDL cholesterol metabolism, VLDLs are synthesized in liver cells 
(hepatocytes) through packaging with TG, cholesterol and apolipoprotein B isoform 
B100. TG in VLDLs can be lipolyzed by LPL, resulting in the release of free fatty 
acids and monoacylglycerols from VLDLs to form VLDL remnants. A small amount 
of VLDL remnants are cleared by hepatic receptors, whereas the majority in the 
plasma are subsequently converted to LDL through CETP. LDL transports 
unesterified and esterified cholesterol from the liver to the periphery. During the 





In HDL cholesterol metabolism, apolipoprotein A1 (ApoA1) is synthesized in the 
liver and released to the periphery. These particles interact with ATP-binding cassette 
A1 (ABCA1) transport proteins expressed in the peripheral cells. ABCA1 catalyzes 
the transfer of unesterified cellular cholesterol. Subsequently, ApoA1 accumulates 
cholesterol and phospholipids, leading to the generation of nascent pre-HDL. The 
nascent pre-HDL is remodeled by lecithin-cholesterol acyltransferase (LCAT), 
phospholipid transfer protein and CETP, thus completing the transformation to 
mature HDL. These HDL particles continue to pick up free cholesterol from the 
13 
 
peripheral tissues with the help of ATP-binding cassette transporter G1, and then 
transport cholesterol to the liver. HDL particles are removed from the bloodstream 




Lipoproteins, atherosclerosis and cardiovascular disease 
Lipid metabolism is essential for sustaining normal cell function, and disturbance of 
this process can have serious consequences for organisms. Atherosclerosis and 
cardiovascular disease (CVD) are major diseases related with cholesterol and 
lipoprotein metabolism in human
7, 8
. Atherosclerosis is a progressive disease which is 
characterized by the accumulation of lipids in the large arteries. It has been 
demonstrated that atherosclerosis causes about 50% of all deaths in westernized 
societies
1
. Epidemiological and genetic disorder studies have revealed that several 
important environmental and genetic risk factors are associated with atherosclerosis 
and CVD, such as higher LDL/VLDL levels, reduced HDL levels, elevated blood 
pressure, diabetes, obesity, family history, systemic inflammatory, smoking and lack 
of exercise
1
. Of the factors, the relative abundance of several plasma lipoproteins 




Plasma lipoproteins and CVD risk 
Clinical trials have shown that elevated concentrations of plasma LDL cholesterol are 
associated with increased in coronary heart disease
66, 67
. Plasma LDLs are normally 
catabolized through receptor-mediated endocytosis. Chronic excess of plasma LDL 
interrupts arterial relaxation. Moreover, LDL particles, which fail to be removed 
14 
 
through receptor-mediated pathway, can be recognized by scavenge receptors on 
arterial-wall macrophages
1, 68
. Once LDLs are engulfed by macrophages, they 
become oxidized and induce toxic intermediates, leading to cytokine production and 
taxis of inflammatory cells
68
. In addition, arterial-wall macrophages loaded with LDL 





Unlike LDLs, HDL cholesterol levels are inversely correlated with cardiovascular 
risk
69
. Epidemiological studies show that a 1 mg/dl increase in HDL cholesterol 
contributes to a 2-3% decrease in the risk of CVD
70
. It is well known that the primary 
physiological role of HDLs is reverse cholesterol transport (RCT) (i.e., the centripetal 
transport of cholesterol from the peripheral tissues to the liver). Cholesterol carried by 
HDLs particles might be cleared in the liver by the scavenger receptor B1 mediated 
pathway
71
. Therefore, HDLs help to maintain total circulating cholesterol within its 
correct range. Besides „reverse cholesterol transport‟, HDLs have various protective 
properties, including anti-inflammatory, antioxidative, anticoagulant, and 





Plasma lipoproteins and atherosclerosis 
Progressive accumulation of cholesterol in the arterial wall causes atherosclerosis. A 
classic study reported in 1913 by Anitschkow and Chalatow demonstrated that 
cholesterol-fed rabbits showed atherosclerotic plaques in their arteries, which 
15 
 
indicated a causal role of cholesterol in atherosclerotic plaque development
74
. 
Subsequently, epidemiological studies confirmed that increased blood cholesterol 




As the major carrier of cholesterol, LDLs have been associated with the development 
of atherosclerosis. It has been demonstrated that the early lesions of atherosclerosis 
are composed of subendothelial accumulation of cholesterol-engorged macrophages, 
termed „foam cells‟, which have a key role in atherogenesis
1
. The accumulation of 
LDL in the subendothelial matrix initiates an atherosclerosis process. LDL retention 
in the subendothelium of vessel wall seems to be related to the interactions between 
LDL constituent apolipoprotein B (ApoB) and matrix proteoglycans
76
. Besides LDL, 
lipoprotein (a), a particle resembling LDL but containing ApoB and 
apolipoprotein(a), can retain in the intima and promote atherosclerosis
77
. 
Furthermore, LDLs undergo modification, including oxidation, aggregation and other 
means, to induce a series of biological responses that result in atherosclerosis
78
. 
Aggregated LDL is a major LDL modification in atherosclerotic lesions, which 
delivers enormous amounts of cholesterol to macrophages and results in the 




However, HDL is very protective against atherosclerosis. The primary mechanism 
underlying this protective effect is the role of HDL in reverse cholesterol transport 
(carrying excess cholesterol from foam cells to the liver)
10
. In addition, HDL 
possesses antioxidant, anti-inflammatory, and antithrombotic properties, which 
16 
 
contribute to protection against atherosclerosis. For example, HDL interferes with an 
initial process of atherogenesis by inhibiting LDL oxidation. Recently, besides 
lowering LDL cholesterol levels, raising HDL cholesterol has emerged as a potential 




Adiponectin and atherosclerosis 
Adiponectin, one of adipocytokines 
Adipose tissue is now considered to be not only a passive energy store, but also an 
important endocrine organ. Indeed, adipose tissue produces a range of bioactive 
cytokines called “adipocytokines”
80
. Leptin, resistin, visfatin and adiponectin are 
adipocytokines. Research conducted over the past several years has revealed that 
adipocytokines can affect lipid metabolism
81
 and that absence or excess of individual 
adipocytokines causes obesity, potentially leading to diabetes and cardiovascular 
disease
82
. Leptin is primarily involved in regulating food intake and energy 
expenditure. Recent studies showed that leptin exerts many potentially atherogenic 
effects and plays an important role in cardiovascular diseases
83
. It has been found that 
increased levels of plasma resistin were positively correlated with cardiovascular 
risk
84
. Visfatin, a adipocytokine secreted by visceral fat, mimics insulin activity by 
binding to the insulin receptor
85
. Compared with the aforementioned factors, 
adiponectin has exhibited different biological properties. Unlike leptin and resistin 
which are pro-inflammatory cytokines, adiponectin is considered to be an anti-
inflammatory cytokine
86





. Thus, adiponectin is perhaps the most promising of the 
adipocytokines for the development of therapeutic strategies.  
 
Adiponectin 
Adiponectin was identified independently by four research groups in 1995 and 1996. 
Subsequently it was also termed as AdipoQ
88
, Acrp30 (adipocyte complement-related 
protein 30)
89
, apM1 (adipose most abundant gene transcript 1)
90
,  and GBP28 
(gelatin-binding protein 28)
91
. Adiponectin is a 30 kDa adipocytokine hormone 
synthesized mainly by adipose tissue in several animal species. It is a 244 amino acid 
protein and consists of a N-terminal collagen domain that is responsible for building 
tertiary structure and a C-terminal globular domain that is important for mediating 
adiponectin effects
92
. Adiponectin exists as a full-length protein as well as a cleavage 
fragment, which is known as globular adiponectin and consists only of the C-terminal 
globular domain
93
. Full-length adiponectin can oligomerize via the N-terminal 
collagen domain to form a trimer (low-molecular-weight adiponectin), a hexamer 




Adiponectin is mainly synthesized by adipocytes. Recent studies have found that it is 




 and endothelial cells
97
. 
Adiponectin cDNA in the chicken is 65-68 % homologous to different mammalian 
adiponectin and is expressed at the highest levels in adipose tissue, followed by the 
liver and anterior pituitary
98
. In humans, adiponectin circulates at high concentrations 





 (compared with leptin circulating at a concentration of a few ng per ml). It 
has been reported that plasma adiponectin levels are influenced by different factors, 
such as age, gender and lifestyle. Indeed, women have higher plasma adiponectin 
levels than men
100
. Some dietary factors, such as soy protein and fish oils, also 





Two adiponectin receptors have recently been identified (AdipoR1 and AdipoR2). 
Both AdipoR1 and AdipoR2 are seven transmembrane receptors, in which the N-
terminus is internal and the C-terminus is external. These receptors are structurally 
distinct from G-protein-coupled receptors
102
. AdipoR1 is widely expressed, 
particularly in skeletal muscle, whereas AdipoR2 is most abundantly expressed in the 
liver
102
. AdipoR1 and AdipoR2 have been found to be structurally conserved in 
several animals, including the chicken
103
. Moreover, two types of adiponectin 
receptors have been demonstrated to have different affinities for binding globular and 
full-length adiponectin. AdipoR1 has a higher affinity for the globular adiponectin 
whereas AdipoR2  mainly engages with full-length adiponectin
102
. Globular and full-
length adiponectin can bind to both receptors and mediate the activation of 5' 
adenosine monophosphate-activated protein kinase (AMPK) 
104,105 
 and the 
peroxisome proliferator activated receptor (PPARα)
106
, thus exerting its biological 
functions. Different functions between AdipoR1 and AdipoR2 in adiponectin signal 
pathways have been reported. AdipoR1 may be associated with the activation of 
19 
 





Adiponectin as a key mediator of diseases 
Adiponectin is a hormone that is secreted predominantly by adipocytes. Adiponectin  
acts as a major anti-diabetic, anti-atherogenic and anti-inflammatory adipocytokine. 
Adiponectin has been shown to play crucial roles in regulating glucose and lipid 
metabolism
104, 108




. Recent research 
has revealed that low plasma adiponectin levels, known as hypoadiponectinaemia, are 
associated with various disease conditions. 
 
Adiponectin in atherosclerosis and cardiovascular disease 
Adiponectin acts as a major anti-atherogenic and anti-inflammatory adipocytokine. 
Several clinical reports indicated that low levels of adiponectin are associated with 
the development of cardiovascular disease
111, 112, 113
. It has been demonstrated that 
inflammation is an essential factor in the initiation and development of 
atherosclerosis
114
. As previously mentioned, adiponectin inhibits the secretion of 
inflammatory cytokines, such as TNF in the atherogenic process, thus suppressing the 
expression of TNF-induced adhesion molecules in endothelial cells
115
. Adiponectin 
also inhibits foam cell formation
116
 and reduces proliferation and migration of smooth 
muscle cells
117
. Considering that atherosclerosis is an inflammatory disease
114
, the C-
reactive protein (CRP), a proinflammatory marker, is one of the most reliable 
biomarkers to assess cardiovascular risk
118
. It has been found recently that levels of 
20 
 
adiponectin in plasma and adipose tissue were negatively correlated with CRP 




It has been hypothesized that adiponectin plays both direct and indirect roles in 
protection against cardiovascular disease
120
. There is increasing evidence that the 
protection effect of adiponectin is due to its involvement in regulating both lipid and 
carbohydrate metabolism. It is important to note that in the Women‟s Health Study, 
cholesterol was the strongest predictor for future cardiovascular events, including 
low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C) and total cholesterol
121
. Low levels of plasma adiponectin have been 
reported to be related to small dense LDL, high triglyceride, and apolipoprotein B 
(APOB) levels
122
. It has also been found that adiponectin directly acts on vascular 
endothelium and protects against cardiovascular disease in part because of the 
reduction of lipid accumulation in macrophages
123
. Furthermore, administration of 




Adiponectin in obesity, insulin resistance and diabetes 
It has been demonstrated that plasma adiponectin levels are reduced in obesity, 
insulin resistance, and type 2 diabetes
125
. Adiponectin expression in adipose tissue 
and circulating levels in plasma are decreased in several animal models of obesity
126
. 
Studies in different human populations, including Japanese and Asian Indians, have 
also shown that low plasma adiponectin levels are predictors for future development 
of diabetes and insulin resistance
127,128,129
. It has also been found that simultaneous 
21 
 
disruption of AdipoR1 and AdipoR2 reduced adiponectin-specific binding and 
adiponectin sensitivity. Conversely, the increasing expression of either AdipoR1 or 
AdipoR2 in the liver ameliorated insulin resistance and diabetes
107
. Administration of 
adiponectin induced glucose-lowering effects and ameliorated insulin resistance in 
mice
93,126,130
, whereas adiponectin-deficient mice exhibited insulin resistant and 
diabetic
108,131
. It has been reported that the adiponectin effect in insulin sensitivity may 





. It is well known that AMPK has a crucial role in 
regulating body weight, food intake, and glucose and lipid homeostasis, thereby 
controlling the systemic energy balance
132
. Moreover, AdipoR1 and AdipoR2, the 
major receptors for adiponectin, serve as key physiological regulators for the glucose-




Adiponectin in inflammation 
In metabolic diseases, such as obesity and diabetes, inflammation in the systemic 
microcirculation is widely known to lead to organ damage and other chronic 
complications. Among many proteins secreted by adipocytes, adiponectin serves a 
unique role as an anti-inflammatory and anti-atherogenic factor. It has been 
demonstrated that adiponectin exerts various anti-inflammatory effects, which include 
inhibition of pro-inflammatory cytokine production, induction of anti-inflammatory 
factors, and reduction of the expression of adhesion molecules
134
. Adiponectin-
deficient mice have higher expression levels of  tumor necrosis factor (TNF; a pro-
inflammatory cytokine) mRNA in adipose tissue and higher plasma TNF 
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concentrations than adiponectin-sufficient mice
131
. In addition, adiponectin inhibits 
nuclear factor-κB (NF-κB) activation in endothelial cells and influences the function 
of macrophages
135
. Besides inhibiting the production of pro-inflammatory cytokines, 
adiponectin also induces the production of several important anti-inflammatory 





In the model of MDV-induced atherosclerosis, Fabricant et al. reported that 
atherosclerotic lesions were observed in large coronary arteries and aortas of both 
normocholesterolemic (relatively poor diet in cholesterol) and hypercholesterolemic  
( 2 % cholesterol supplement) chickens by infection with MDV whereas no arterial 
diseases developed in uninfected chickens fed either cholesterol-poor or cholesterol-
supplemented diets
3, 5
. These results provided direct evidence suggesting 
herpesviruses as potential initiators of arterial injury. The same group subsequently 
found that MDV infection caused atherosclerosis in the chicken while those animals 
that were previously vaccinated and later challenged with MDV did not exhibit total 
aortic lipid accumulation
4
. These results suggested that MD resistance induced by 
vaccination could prevent the development of atherosclerosis caused by MDV 
infection. Two main strategies for resistance of MD have been demonstrated: 
vaccination and genetic resistance to MD
40
. It has been demonstrated that prior 
vaccination with the turkey herpesvirus could prevent atherosclerosis in MDV-
infected chickens
4, 6
. Therefore, it is very interesting to explore the role of genetic 
resistance in the progression of herpesvirus-induced atherosclerosis. Furthermore, the 
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role of lipoprotein metabolism in atherosclerosis induced by MDV infection remains 
elusive although the role of cholesterol metabolism has been demonstrated for 
decades. The present study was conducted to compare the effects on lipoprotein 
metabolism induced by MDV infection between MD resistant and susceptible chicken 
lines. We hypothesized that lipoprotein metabolisms is different in distinct MD 
susceptible and resistant lines. To test this hypothesis, two experiments were designed 
1) to determine whether differences exist in the background of lipoprotein 
metabolism between MD resistant and susceptible lines and 2) to assess whether the 
changes of lipoprotein levels in response to MDV infection differ in the MD resistant 
and susceptible lines. Insights from these studies could provide us a better 
understanding of the role of lipoprotein metabolism in herpesvirus induced 











Chapter 2: Comparison of lipoprotein metabolism in MD resistant       
and susceptible chicken lines 
Introduction 
Atherosclerosis is one of the main human diseases involving cholesterol and 
lipoprotein metabolism
7, 8
. Although a cholesterol accumulation in artery walls is  the 
defining characteristic of atherosclerosis
91
, lipoproteins also play an important role in 
the development of the disease. It has been demonstrated that LDL is a risk factor for 
atherosclerosis
9
, whereas HDL is a protective factor against atherosclerosis
10
. Raising 
HDL cholesterol and lowering LDL cholesterol have, thus, emerged as potential 
strategies to lower the risk of developing atherosclerosis
10
. MDV infection can induce 
atherosclerosis in chickens
3-5
. It has been reported that MDV infection induced aortic 
lipid accumulation, including cholesterol, cholesterol ester, triacylglycerol and 
phospholipids
4
. The lipid accretion in aortas of MDV infected chickens may have 
been a result of alterations in cholesterol metabolism
4, 6
. 
Lipoproteins, the key carrier of cholesterol through the circulating system, 
fundamentally modulate cholesterol metabolism. Thus, lipoprotein metabolism may 
play an important role in MDV- induced atherosclerosis. We hypothesized that MDV 
influences lipoprotein metabolism differently in MD susceptible and resistant lines. 
Therefore, we investigated whether the changes of lipoprotein levels induced by 
MDV differ in the MD resistant and susceptible lines. First we determined whether 
basal lipoprotein metabolism is different between MD resistant and susceptible lines. 
We examined plasma lipoprotein levels and analyzed the phenotype in MD resistant 
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and susceptible lines. We also determined the expression levels of adiponectin and its 
receptors, since adiponectin, as a protective marker against atherosclerosis, 


























To investigate whether any differences in plasma lipoprotein metabolism between 
line 63 and line 72 exist, 2-month-old (growing period) and 15-month-old (mature 
period) chickens from each line were used for analyzing phenotype, determining 
plasma lipoprotein levels, and detecting mRNA and protein expression levels of 









Figure 1. Experimental design for determining the differences of lipoprotein 
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Methods and materials 
Phenotype data 
At the end of each study, animals were weighed and then sacrificed for blood and 
tissue collection. Tissue samples were weighed, and immediately frozen in liquid 
nitrogen and stored at -80 ℃. The weight percentage of each tissue was calculated by 
the equation:  
Tissue percentage =  
 
Plasma HDL and LDL/VLDL cholesterol levels 
Blood samples were drawn by cardiac puncture and placed in 10 ml tubes with 
EDTA. Plasma was separated from whole blood by centrifugation at 2000   g for 20 
min and kept at 4 ℃ until analysis. Plasma total cholesterol, HDL cholesterol and 
LDL cholesterol were measured using a HDL and LDL/VLDL cholesterol 
quantification kit (BioVision, Exton, PA).  
Real-time quantitative PCR 
Total RNA was extracted from abdominal fat and liver by using RNeasy mini kit 
(Qiagen Inc., Valencia, CA) following the manufacture‟s protocol. Total RNA was 
quantified according to UV absorbance (260/280 nm) using a spectrophotometer ND-
1000 (Thermo Fisher Scientific Inc., Wilmington, DE). Complementary DNA 
(cDNA) was synthesized by reverse transcribing 800ng total RNA using an oligo-dT 
(12-18) primer and Superscript II reverse transcriptase (Invitrogen). Primers used to 
Tissue weight (g) 
Body weight (g) 
  100% 
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amplify adiponectin, adipoR1, adipoR2
137
 and GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) were described as follows: 
Adiponectin: Forward 5‟-ACAGGTGCAGAAGGACCGAGAGGATT-3‟ 
                      Reverse 5‟-AAGACAGAGCCGCTTGCTTGGTCAAC-3‟ 
AdipoR1: Forward 5‟-GAATACACACCGAGACGGGCAACATCT-3‟ 
                 Reverse 5‟-GCCCAAGACGCAGACAATGGAGAGGTA-3‟ 
AdipoR2: Forward 5‟-GAGACTGGCAACATCTGGACGCATCTTC-3‟ 
                 Reverse 5‟-TGCGATGCCCAGGACACAAATCACAAT-3‟ 
GAPDH: Forward 5‟-TGACTTCAATGGTGACAGCC-3‟ 
                 Reverse 5‟-ACTCCTTGGATGCCATGTGG-3‟ 
The products of the reverse transcription reaction were diluted (5  ) with ddH2O, and 
1 μl was used as a template in real-time polymerase chain reaction (RT-PCR). The 
RT-PCR was performed using a SYBR Green RT-PCR kit (Qiagen Inc.). The PCR 
reaction was carried out using the following program: 95 ℃ for 15 min, 40 cycles of 
94 ℃ for 15 s, 57 ℃ for 30s and 70 ℃ for 30s. For a negative control, water was 
used as a template in place of single strand cDNA during RT-PCR. The quantitative 
PCR (qPCR) output provided the log-linear threshold values (CT) for the threshold 
cycle. Samples from each animal were measured in duplicate to obtain average CT 
values for each mRNA. Values were transformed to a ∆Ct value by normalizing gene 
expression to the housekeeping gene GAPDH using the following equation: ∆Ct = 
(Average Ct-target – Average Ct-GAPDH).  The ∆∆Ct value was then calculated by 
subtracting the sample Ct value from the sample with the highest expression level for 
controlling amplification efficiency. Results were then converted from log-linear to 
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linear terms by the function: 2
-∆Ct
.  The relative mRNA expression of adiponectin, 
adipoR1 or adipoR2 in various groups was compared.  
Western blot 
Protein extraction 
Protein extracts from chicken abdominal fat and liver were prepared as described 
previously
138
, with slight modifications. Briefly, 0.2-0.3g of abdominal fat and liver 
were homogenized using a pestle in 2 ml lysis buffer (10mM Tris-HCl, 150mM 
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease 
inhibitor cocktail (Sigma). The homogenate was shaken in a thermomixer at 1000 
rpm for 2 hour at 4 ℃, and the lysates were then centrifuged at 14,000   g for 20 min 
at 4 ℃. The supernatant was collected, and total protein concentration was measured 
using a Victor 1420 multilable counter (PerkinElmer). Chicken plasma was used 
directly for western blot analysis to determine protein levels of adiponectin in the 
plasma. 
Western blot 
Protein samples were prepared for electrophoresis by heating with SDS-PAGE 
Laemmli buffer (50mM Tris-HCl, 10% glycerol, 2% SDS, 0.05% bromophenol blue, 
pH 6.8) containing 10% β-mercaptoethanol (Promega, Madison, WI) for 10 min at 
100 ℃. Proteins were separated by SDS-PAGE in 10% (w/v) polyacrylamide gels139 
at 120v for 90 min. After separation by SDS-PAGE, proteins were transferred onto a 
PVDF membrane. The membranes were blocked with SuperBlock T20 blocking 
buffer (Pierce, Rockford, IL) for 1 h at room temperature. The membranes were then 
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incubated with primary antibodies (rabbit anti-chicken adiponectin, adipoR1 and 
adipoR2 from Dr. Ramesh Ramachandran) at 4 ℃ for 24 h. The antibodies were 
diluted with SuperBlock T20 (adiponectin in plasma and abdominal fat (1:40,000); 
adipoR1 and adipoR2 in liver (1:2,000) and abdominal fat (1:500)). The membranes 
were washed three times with 1   Tris-Buffered Saline Tween-20 (TBST) for 5 min 
each and then incubated with secondary antibody donkey anti-rabbit IgG (Santa Cruz 
Biotechnology) (diluted by 1:5,000) for 1 h at room temperature. The membranes 
were then incubated with ECL chemiluminescense detection reagent (GE Healthcare, 
Piscataway, NJ). 
Chemiluminescent signal was collected using a ChemiDoc XRS imaging system 
(Bio-Rad Laboratories, Hercules, CA).  The protein bands were quantified using 
Quantity One software (Bio-Rad). The molecular weights of proteins were estimated 
using Pageruler plus prestained protein ladder (Fermentas international Inc., Canada). 
Stripping and reprobing β-actin 
Primary and secondary antibodies were removed from the membranes by incubating 
with Western Blot Stripping Buffer (20 ml 10% SDS, 12.5 ml Tris-HCl, 0.8 ml β-
mercaptoethanol, 67.5 ml ddH2O, pH 6.8) for 40 min at 50 ℃. The membranes were 
blocked with 5% nonfat dried milk for 1 h and then incubated with anti-β-actin 
antibody (Santa Cruz Biotechnology) (1:1,000 diluted with 1   TBST) at 4 ℃ for 24 
h. The membranes were incubated with donkey anti-mouse IgG (Santa Cruz 
Biotechnology) (1:10,000 diluted with 1   TBST) for 1 h at room temperature. The 




The data were analyzed with a two-way ANOVA followed by Tukey‟s test for 
comparison among different groups using Statistical Analysis System v.9.1 (SAS 
Institute, Cary, NC). Values shown are means ± S.D (Standard deviation). 
The statistical model for 2 month- and 15 month-old chicken was: 
Y = μ + Li + Aj + Li*Aj + εi, j, k 
The line, age and their interaction are treated as fixed factors in the model. 
    μ: grand mean; 
    Li: the effect of the ith line (63 or 72) on Y; 
    Aj: the effect of the jth age (2 months or 15 months) on Y; 














Phenotype analysis for 2 month- and 15 month-old chickens from line 63 and 72 
    To investigate whether there were differences in body weight and tissue weight 
percentage between line 63 (L63) and line 72 (L72), abdominal fat, breast muscle with 
bone, leg muscle with bone, liver, heart and spleen samples were collected from 
chickens at 2 months and 15 months of age. The statistical model used to analyze 
these phenotypes was Y = μ + Li + Aj + Li*Aj + εi, j, k; including line, age and the 
interaction between line and age, all as fixed effects. The interactions between line 
and age were found to be non-significant for body weight, breast muscle with bone, 
leg muscle with bone and heart. The body weights were not statistically different 
between L63 and L72 in the two age chickens. However, an obvious increase in body 
weight was observed in 15 month-old chickens as compared to 2 month-old chickens 
in L63 (1788.11 ± 36.26 vs. 1184.75 ± 54.39 g) and L72 (1880.67 ± 36.26 vs. 1319.00 
± 54.39 g) (Figure 2a). We also observed a lower percentage of leg muscle with bone 
in L72 in compared to L63 in 15 month-old chickens (p < 0.01) (Figure 2d). L72 also 
had significantly higher heart percentage at 2 months and 15 months of age compared 
to L63 (p < 0.001) (Figure 2f). However, no difference between the lines was apparent 
for the percentage of breast muscle with bone (Figure 2c). 
The interactions between line and age were significant for abdominal fat (p<0.001), 
liver (p<0.001) and spleen (p<0.05), so data for the three phenotypes were analyzed 
within each age. The abdominal fat percentage was not different between L63 and L72 
at 2 months of age (2.51 ± 0.55 vs. 2.97 ± 0.55 %), but L63 had significantly higher 
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abdominal fat percentage than L72 (7.58 ± 0.37 vs. 4.36 ± 0.37 %, p < 0.001) (Figure 
2b) at 15 months of age. L72 also had significantly higher liver weight percentage at 
15 months of age and higher spleen weight percentage at 2 months of age compared 
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Figure 2. Phenotype data for 2 month- and 15 month-old chickens. 
Body and tissue weight were measured for 2 month-old (n = 4) and 15 month-old (n = 
9) chickens in line 63 (blue bar), and for 2 month-old (n = 4) and 15 month-old (n = 9) 
chickens in line 72 (purple bar). Tissue percentages were calculated by ((Tissue 
weight) / (Body weight)) *100%. (a), Body weight (g); (b), Abdominal fat percentage 
(%); (c), The percentage of breast muscle with bone (%); (d), The percentage of leg 
muscle with bone (%); (e), Liver percentage (%); (f), Heart percentage (%); (g), 
Spleen percentage (%). Values were shown as means ± S.D. (means ± standard 
deviation). Letters identify differences among groups; thus, two groups not sharing 
lowercase letters are significantly different (two-way ANOVA, Tukey‟s test, p<0.05). 











Plasma lipoprotein levels for line 63 and line 72 at 2 months and 15 months of age 
To determine whether there was a difference in lipoprotein metabolism between L63 
and L72, plasma lipoprotein concentrations were measured in 2 month- and 15 month-
old chickens (Figure 3). Results of total cholesterol revealed that L63 contained total 
cholesterol 0.50 ± 0.11 μg/μl at 2 months of age and 0.84 ± 0.09 μg/μl at 15 months 
of age, while L72 contained total cholesterol 0.66 ± 0.14 μg/μl and 1.36 ± 0.09 μg/μl, 
respectively (Figure 3a). With respect to individual lipoprotein classes, HDL 
cholesterol had a modest increase in both chicken lines during growth, but there were 
no significant differences between the lines (p > 0.05) (figure 3b). As for the 
(LDL+VLDL) cholesterol levels, the interaction between line and age was significant 
(p<0.001). We observed that (LDL+VLDL) cholesterol levels in L63 and L72 were 
not significantly different (p > 0.05) at 2 months of age (Figure 3c). However, at 15 
months of age, L72 had 247% more (LDL+VLDL) than L63 (p < 0.001) (Figure 3c). 
Moreover, significant interactions between line and age were also observed in HDL 
ratio (p<0.01) and (LDL+VLDL) ratio (p<0.01).   
Results of HDL ratio revealed no significant difference between 2 month- and 15 
month-old chickens in L63 (0.62 ± 0.059 vs. 0.74 ± 0.048, p > 0.05), whereas there 
was a significant decrease in 15 month-old chickens (0.42 ± 0.05) compared to 2 
month-old chickens (0.70 ±  0.07) in L72 (p < 0.05) (Figure 3d). Correspondingly, a 
significant increase in (LDL+VLDL) ratio was observed in 15 month-old chickens 
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Figure 3. Plasma lipoprotein levels for 2 month- and 15 month-old chickens. 
 
Lipoprotein concentrations were measured for 2 month-old (n = 6) and 15 month-old 
(n = 9) chickens in line 63 (blue bar), and for 2 month-old (n = 4) and 15 month-old (n 
= 9) chickens in line 72 (purple bar). (a), Total cholesterol (μg/μl); (b), HDL 
cholesterol (μg/μl); (c), LDL+VLDL cholesterol (μg/μl); (d), Lipoprotein ratio. In (a), 
(b), and (c), values were shown as means ± S.D. Letters identify differences among 
groups; thus, two groups not sharing lowercase letters are significantly different (two-

















Adiponectin, adipoR1 and adipoR2 gene expression 
Adiponectin has been associated with favorable effects on metabolism (i.e. reduced 
visceral adipose mass, decreased plasma LDL cholesterol, and increased HDL 
cholesterol)
140
. The biological effects of adiponectin are mainly mediated by two 
receptors (adipoR1 and adipoR2) 
87
. As our biochemical experiments of plasma 
lipoprotein levels suggested that total cholesterol and LDL cholesterol levels were 
different between the two lines, we further tested whether the levels of adiponectin, 
adipoR1 and adipoR2 were different in L63 and L72. Using RT-PCR, we found no 
significant difference in adiponectin mRNA levels in abdominal fat among the four 
groups (L63-2months, L72-2months, L63-15months, L72-15months) (Figure 4a). 
AdipoR1 mRNA quantities in liver and abdominal fat were slightly lower in L72 
compared with that in L63 (Figure 4b, 4c). Furthermore, adipoR2 mRNA quantities in 
liver and abdominal fat were not significantly different (p > 0.05) between L63 and 
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Figure 4. mRNA levels of adiponectin, adipoR1 and adipoR2 by qPCR for line 63 
(blue bar) and 72 (purple bar) at 2 months and 15 months of age (n=4).  
(a), Adiponectin in abdominal fat; (b), AdipoR1 in liver; (c), AdipoR1 in abdominal 
fat; (d), AdipoR2 in liver; (e), AdipoR2 in abdominal fat. GAPDH mRNA expression 
was used for normalization. Values were shown as means ± S.D. Letters identify 
differences among groups; thus, two groups not sharing lowercase letters are 
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Adiponectin, adipoR1 and  adipoR2 protein expression 
In light of the role identified for adiponectin in regulating plasma lipoprotein levels, 
we next examined protein expression levels for adiponectin and its receptors in L63 
and L72 using western blots (Figure 5). Duplicates from each group were conducted 
in western blots. Lane 1 and 2 were designed for L63-2months; Lane 3 and 4 for L72-
2months; Lane 5 and 6 for L63-15months; Lane 7 and 8 for L72-15months. Detection 
of β-actin in the same blot was used for normalization. Results were quantified by 
calculating the ratio of the density of the protein band and β-actin band. The results 
showed that adiponectin levels in abdominal fat were not significantly different 
among the four groups (p > 0.05) (Figure 5a), indicating that L63 and L72 may have 
synthesized a similar amount of adiponectin as adiponectin is primarily synthesized in 
abdominal fat
87
. However, there was a significant decrease in the level of adiponectin 
in plasma in L72 (5.91 ± 0.58) compared to that in L63 (11.41 ± 0.58) at 2 months of 
age (p < 0.01, Figure 5b).  
 
Moreover, our results revealed that L63-2 month-old chickens had the highest level of 
adiponectin, followed by L72-2 months, L63-15months, and L72-15months. 
Interestingly, this trend seems to be inversely correlated to the change of total 
cholesterol concentration within four groups, which showed the highest level in L72-
15months, followed by L63-15months, L72-2months, and L63-2months (Figure 3b).  
In order to determine the negative correlation, plasma adiponectin levels for four 
chickens from each group were detected. We then analyzed the correlation coefficient 
between plasma adiponectin levels and total cholesterol concentrations (Figure 3g). 
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The statistical analysis showed that correlation coefficient (r) was -0.800 when an 
outlier (for which total cholesterol concentration is 1.62 ug/ul) was removed from the 
data set. These results are consistent with others‟ report that plasma adiponectin 




We also examined protein expression levels of adipoR1 and adipoR2 in liver and 
abdominal fat. Quantitative results revealed that there were no differences in adipoR1 
in the liver between the two lines at 2 months and 15 months of age (p > 0.05, Figure 
5c). It should be noted that no remarkable differences were observed between L63-
2months and L63-15months groups, whereas a significant decrease in adipoR1 levels 
in the liver was detected in L72-15months (4.06 ± 0.64) compared to L72-2months 
(7.49 ± 0.64) (p < 0.05, Figure 5c). Quantitative results of adipoR1 in abdominal fat 
revealed no differences between the two lines in 2 month-old chickens (p > 0.05, 
Figure 5d). However, at 15 months of age, L72 had a significantly higher level of 
adipoR1 (6.21 ± 0.39) compared to L63 (3.54 ± 0.39) (p < 0.05, Figure 5d). 
Interestingly, L72-15months showed the lower level of adipoR1 in liver and the 
higher level of adipoR1 in abdominal fat. No significant differences in adipoR2 
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Figure 5. Adiponectin, adipoR1 and adipoR2 protein levels in 2 month- and 15 
month-old chickens from line 63 and line 72.  
(a), Adiponectin in abdominal fat; (b), Adiponectin in plasma; (c), AdipoR1 in liver; 
(d), AdipoR1 in abdominal fat; (e), AdipoR2 in liver; (f), AdipoR2 in abdominal fat. 
For lane 1, 2, 3, 4, 5, 6, 7 and 8, every two lanes represent protein samples of two 
birds f one of the four groups (line 63 2 months of age, line 72 2 months of age, line 63 
15 months of age, line 72 15 months of age), respectively. Detection of β-actin in the 
same blot was used for normalization. The level of protein expression is presented as 
relative fold in comparison with β-actin levels. With respect to chicken plasma, the 
same volume of plasma (1 μl) was used in each sample, and quantitative results were 
calculated by dividing the density of the protein band by 50. Values were shown as 
means ± S.D. Letters identify differences among groups; thus, two groups not sharing 
lowercase letters are significantly different (two-way ANOVA, Tukey‟s test, p<0.05). 
(g), Correlation analysis between plasma adiponectin levels and total cholesterol 












The above experiments were designed to study the baseline lipoprotein metabolism in 
MD susceptible and resistant lines. Our results revealed no significant differences in 
HDL cholesterol between the two lines. However, (LDL+VLDL) levels were more 
than three-fold greater in L72 than in L63 at 15 months of age. During chicken growth 
from 2 months to 15 months of age, total cholesterol was only slightly increased in 
the MD resistant line (L63), but it was markedly enhanced in the MD susceptible line 
(L72). Notably, the increase in total cholesterol in the resistant line mainly resulted 
from an increase in HDL, whereas the increased total cholesterol in the MD 
susceptible line was due mostly to the elevation of (LDL+VLDL).  
 
These findings led us to investigate possible mechanisms that are responsible for the 
changes in lipoprotein content during growth between MD susceptible and resistant 
lines. Adiponectin, a protective marker against atherosclerosis, is known to 
fundamentally influence lipoprotein metabolism
81
. Thus, we next studied whether or 
not the adiponectin pathway is responsible for the different lipoprotein changes 
between the two lines. Our results revealed no significant differences in the 
adiponectin levels synthesized from abdominal fat. However, L72 had significantly 
lower circulating levels of adiponectin compared to L63 in both 2 month- and 15 
month-old chickens. Furthermore, the MD susceptible line at 15 months of age, with 
significantly higher level of LDL cholesterol, possessed a modestly lower level of 
adipoR1 in liver and an obviously higher level of adipoR1 in abdominal fat compared 
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to the other three groups. There were no significant differences in adipoR2 expression 
levels between L63 and L72 in both liver and abdominal fat.  
 
We also studied the phenotype of MD susceptible and resistant lines, including body 
weight, the weight percentage of abdominal fat, breast muscle with bone, leg muscle 
with bone, liver, heart and spleen. The phenotype analysis revealed no significant 
difference in body weight between L63 and L72. However, L72 had a much lower 
percentage of abdominal fat and leg muscle with bone than L63 at 15 months of age. 
Conversely, L72 had a significantly higher percentage of liver weight at 15 months of 
age, of spleen weight at 2 months of age, and of heart weight in both ages compared 
to L63. There were no significant differences in the weight percentage of breast 
muscle with bone between the two lines. Taken together, our results demonstrated 











Chapter 3: lipoprotein levels in response to MDV infection in MD 
resistant and susceptible lines 
Introduction 
MDV infection can induce atherosclerosis in chickens
3-5
. It has been known that a 
cholesterol accumulation in artery walls is the defining characteristic of 
atherosclerosis
91
. Researches demonstrated that MDV infection induced aortic lipid 
accumulation, including cholesterol, cholesterol ester, triacylglycerol and 
phospholipids
4
. The lipid accretion in aortas of MDV infected chickens was possibly 




Lipoproteins are the key carriers of cholesterol throughout the circulation system, and 
fundamentally influence cholesterol accumulation in the aortas. In MDV induced 
atherosclerosis, it is reasonable to suspect that the cholesterol accretion in the aortas is 
caused by alterations in lipoprotein metabolism. Our results presented that the 
baseline lipoprotein metabolism differs in MD susceptible and resistant lines. We 
further investigated whether MDV infection would influence lipoprotein metabolism 
differently in MD susceptible and resistant chickens. In this study, phenotype analysis 
and plasma lipoprotein levels were conducted for non-infected and infected chickens 







The MD resistant line (L63) and susceptible line (L72) were acquired from the Avian 
Disease and Oncology Laboratory (ADOL) in U.S. Department of Agriculture 
(USDA). To study the influence of plasma lipoprotein levels induced by MDV 
infection, 7-day-old chickens from each line were divided into two groups: one was 
not infected with MDV, one was infected with MDV. Phenotype and plasma 

















MD susceptible line 
(Line 72) 
MD resistant line 
(Line 63) 
Non-infected Infected Infected Non-infected 
21 days post infection 




Methods and Materials  
Phenotype data 
At the end of each study, animals were weighed and sacrificed for blood and tissue 
collection. Tissue samples were weighed, and immediately frozen in liquid nitrogen 
and stored at -80 ℃. The weight percentage of each tissue was calculated by the 
equation:  
Tissue percentage =  
 
Plasma HDL and LDL/VLDL cholesterol levels 
Blood samples were drawn by cardiac puncture and collected in 10 ml tubes with 
EDTA. Plasma was separated from whole blood by centrifugation at 2000   g for 20 
min and kept at 4 ℃ until analysis. Plasma total cholesterol, HDL cholesterol and 
LDL cholesterol were measured using a HDL and LDL/VLDL cholesterol 
quantification kit (BioVision, Exton, PA).  
Statistical analysis 
The data were statistically analyzed using a two-way ANOVA followed by Tukey‟s 
test for comparison among different groups using Statistical Analysis System v.9.1 
(SAS Institute, Cary, NC). Values shown are means ± S.D. 
The statistical model for before or after MDV infection was: 
Y = μ + Li + Tj + Li*Tj +εi, j, k 
 
Tissue weight (g) 
Body weight (g) 
  100% 
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The line, treatment and their interaction are treated as fixed factors in the model. 
    μ: grand mean; 
    Li: the effect of the i
th
 line (63 or 72) on Y; 
    Tj: the effect of the j
th
 treatment (non-infected or infected by MDV) on Y; 






















Phenotype analysis for line 63 and line 72 after MDV infection 
To determine the influence of MDV infection on body weight and various tissues, 
phenotype analysis was performed on L63 and L72 between the non-MDV-infected 
group and MDV-infected group (Figure 7). Although it appeared that body weight 
tended to decrease after MDV infection, no significant difference in body weight was 
detected between non-infected and infected chickens in L63 (358.40 ± 19.24 g vs. 
286.38 ± 21.07 g). However, in L72, there was a significant (p < 0.001) decrease in 
body weight in infected chickens (194.26 ± 21.07 g) compared to non-infected 
chickens (353.30 ± 15.71 g) (Figure 7a). We also assessed whether MDV infection 
would affect tissue weight percentage. Phenotype analysis revealed no significant 
difference in abdominal fat percentage among L63 -non-infected, L63 -infected, L72 -
non-infected, and L72 -infected chickens (Figure 7b). Similarly, there were no 
significant differences in the percentage of breast muscle with bone and of leg muscle 
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Figure 7. Phenotype data for chicken without/with MDV infection. 
 
Body and tissue weight were measured for the non-infected groups (yellow bar) in 
line 63 (n = 6) and line 72 (n = 9), and the infected groups (green bar) in line 63 (n = 5) 
and line 72 (n = 5). Tissue percentages were calculated according to the equation 
((Tissue weight) / (Body weight)) *100%. (a), Body weight (g); (b), Abdominal fat 
percentage (%); (c), The percentage of breast muscle with bone (%); (d), The 
percentage of leg muscle with bone (%). Values were shown as means ± S.D. Letters 
identify differences among groups; thus, two groups not sharing lowercase letters are 
















Plasma lipoprotein levels for line 63 and line 72 after MDV infection 
Previous experiments suggested that cholesterol metabolism was altered in MDV 
infected chickens
4
.  MDV infection is expected to possibly cause a change in 
lipoprotein levels. Thus, we measured plasma lipoprotein concentrations for non-
infected and infected chickens in L63 and L72 (Figure 8). The interaction between line 
and treatment was not significant for total cholesterol, HDL cholesterol and 
(LDL+VLDL) cholesterol (P>0.05). Therefore, we analyzed the effects of line and 
treatment, respectively. In both lines, total cholesterol levels were not significantly 
different between chickens that were infected with MDV and those that were not 
(Figure 8a). However, it should be noted that L72 had higher total cholesterol 
concentration compared to L63 regardless of MDV infection (p < 0.001). 
Furthermore, a slight decrease in HDL cholesterol levels was observed in both lines 
after MDV infection (Figure 8b). Interestingly, MDV infection caused the decrease in 
(LDL+VLDL) levels in L63 (0.082 ± 0.005 μg/μl vs. 0.073 ± 0.005 μg/μl), but caused 
the increase in (LDL+VLDL) levels in L72 (0.087 ± 0.005 μg/μl vs. 0.098 ± 0.005 
μg/μl) (Figure 8c). There was no significant difference between L63 and L72 in the 
non-infected groups. However, in MDV infected groups, L72 had significantly higher 
(LDL+VLDL) concentration compared to L63 (p < 0.05). Moreover, an analysis of 
lipoprotein ratios revealed that MDV infection also induced a slight increase in the 
HDL to total cholesterol ratio and a slight decrease in the (LDL+VLDL) to total 
cholesterol ratio in L63. The opposite was observed in L72 where the HDL ratio 
decreased and the (LDL+VLDL) ratio increased (Figure 8d). 
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Figure 8. Plasma lipoprotein levels for chickens without/with MDV infection (21 
dpi). 
Lipoprotein levels were measured in the non-infected groups (yellow bar) and the 
infected groups (green bar) in line 63 (n = 5) and line 72 (n = 5). Cholesterol 
concentration of each sample was determined using the equation of the standard 
curve. Total cholesterol was calculated by the equation: Total cholesterol = HDL 
cholesterol + (LDL+VLDL) cholesterol. Lipoprotein ratio is represented by two 
different calculations: the ratio of HDL to total cholesterol, and the ratio of 
(LDL+VLDL) to total cholesterol.  
(a), Total cholesterol (μg/μl); (b), HDL cholesterol (μg/μl); (c), LDL+VLDL 
cholesterol (μg/μl); (d), Lipoprotein ratio. In (a), (b), and (c), values were shown as 
means ± S.D. Letters identify differences among groups; thus, two groups not sharing 














In the herpesvirus induced atherosclerosis model, we detected differences in body 
weight and the weight percentage of tissues associated with lipid metabolism such as 
abdominal fat, breast muscle with bone, and leg muscle with bone. A significant 
decrease in body weight was apparent in L72 after MDV infection compared to non-
infected chickens, whereas no significant difference was observed in L63. It has been 
reported that the pathological changes in chickens after MDV infection include 
blindness, immunosuppression, skin lesions and weight loss
37
. Our results concerning 
body weight were consistent with this report. That is, the MD susceptible line (L72) 
experienced weight loss and there were no changes in body weight in the MD 
resistant line (L63). Phenotype analysis revealed that MDV infection did not change 
the percentage of abdominal fat, breast muscle with bone, and leg muscle with bone 
(21 dpi). In fact, MDV infection causes an acute cytolytic infection of lymphoid 
tissues, such as the bursa, thymus and spleen
32
, which may be the underlying causes 
of change in weight percentage in these tissues. Although this study focused on 
tissues involved in lipid metabolism, future studies on lymphoid tissues may provide 
valuable insight for the changes of tissue phenotype caused by MDV infection. 
 
Atherosclerosis is a prominent human diseases that involves cholesterol and 
lipoprotein metabolism
7, 8
. A study of the cholesterol and lipoprotein metabolism in a 
herpesvirus induced atherosclerosis model will help us better understand this disease. 
It has been reported that in MDV infected chickens total aortic lipid accumulation, 
including cholesterol, cholesterol ester, triacylglycerol and phospholipids, increased 
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compared to aortas in uninfected chickens
4, 6
. Lipoproteins are the key carriers of 
cholesterol through the circulating system and play an important role in the 
development of atherosclerosis. Thus, changes in lipoprotein levels would be 
expected in response to MDV infection. Our results revealed that there are no 
remarkable changes in total cholesterol and HDL cholesterol concentrations after 
MDV infection in both chicken lines. Interestingly, in chickens that were not infected 
with MDV, there was no obvious difference in (LDL+VLDL) cholesterol levels 
between line 63 and 72. However, after MDV infection L72 had a significantly higher 
level of (LDL+VLDL) cholesterol than L63. In summary, MDV infection induced a 
modest decrease of (LDL+VLDL) cholesterol level in resistant line 63 but induced an 
increase in susceptible line 72. It has been demonstrated that LDL is an important risk 
factor for atherosclerosis
9
 and that elevated levels of (LDL+VLDL) are associated 
with the development of atherosclerosis
1
. The main physiological roles of VLDLs and 
LDLs are to transport triacylglycerols and cholesterols, respectively, from the liver to 
peripheral tissues. In turn, our findings suggest that the slightly increasing 
(LDL+VLDL) in the MD susceptible line possibly resulted in elevated levels of 
triacylglycerols and cholesterols in the circulating system, thus potentially promoting 









Chapter 4: General discussions 
The present study compared lipoprotein metabolism in MDV susceptible and resistant 
lines. First, we observed that baseline lipoprotein metabolism differed in MD 
susceptible and resistant chicken lines. While the animals were growing, total 
cholesterol lightly increased in the MD resistant line (63)whereas it doubled in the 
MD susceptible line (72). Interestingly, our findings demonstrate that the increase in 
total cholesterol is mainly attributable to the presence of HDL in the resistant line. In 
contrast, in the MD susceptible line, the increase in total cholesterol is mostly due to 
the elevation of (LDL+VLDL).  It has been reported that LDLs serve as the primary 
transport mechanism for transporting cholesterol from the liver to peripheral tissues 
and transport 70-80% of circulating cholesterol
60
. The principal function of VLDLs is 
to transport triacylglycerols from the liver to peripheral tissues. Based on the 
biological functions of VLDLs and LDLs, the elevation of (LDL+VLDL) in L72 
suggests that during chicken growth, the MD susceptible line is more likely to exhibit 
lipid accumulation in peripheral tissues compared to the MD resistant line.  
 
As lipoprotein metabolism is essential to the development of atherosclerosis
7, 8
, it is 
necessary to highlight the physiological significance of different baseline levels of 
lipoprotein between MD susceptible and resistant lines. LDL is a main risk factor for 





results strongly suggest that during growth, the MD susceptible line possessed a 
higher (LDL+VLDL) ratio and correspondingly lower HDL ratio, resulting in an 
increased possibility of developing atherosclerosis.  
 
Adiponectin, a major anti-atherogenic adipocytokine, has characteristics that prevent 
the progression of atherosclerosis. It has been reported that adiponectin 
fundamentally influence lipid metabolism
81
. We next measured adiponectin levels in 
two chicken lines at 2 and 15 months of age. Our results displayed no significant 
differences in both mRNA and protein levels in abdominal fat between the two lines, 
whereas the MD susceptible line had lower levels of plasma adiponectin than the MD 
resistant line. As adiponectin is primarily synthesized in adipocytes
87
, it is possible 
that the MD susceptible line synthesized adiponectin in abdominal fat similar to the 
resistant line, but had lower circulating levels. Adiponectin is a protective factor 
against atherosclerosis. Several reports indicated that lower levers of plasma 
adiponectin are associated with the development of atherosclerosis 
111, 112
. Our results 
indicate that with less circulating adiponectin, as in the MD susceptible line, 
atherosclerosis may be more likely to develop.  
  
Adiponectin exerts its biological functions via two receptors, adipoR1 and 
adipoR2
102
. AdipoR1 is expressed in various tissues and AdipoR2 is expressed most 
abundantly in the liver
102
.  We next measured mRNA and protein expression levels of 
adipoR1 and adipoR2 in liver and abdominal fat. The results of Western blots 
demonstrated that the MD susceptible line at 15 months of age had a lower level of 
72 
 
adipoR1 in liver, but a higher level in abdominal fat was observed. With respect to 
adipoR2, the MD susceptible and resistant line displayed no significant differences in 
both liver and abdominal fat. AdipoR1 may be associated with the activation of 
AMPK pathways, whereas adipoR2 seems to be more tightly linked to activation of 
PPARα pathway
107
. Our results indicate that in the MD susceptible line, adipoR1 may 
activate the AMPK pathway, thus influencing fatty acid oxidation and subsequent 
lipoprotein metabolism. The results from studies of adiponectin and its receptors 
suggest one of the possible mechanisms that may explain the differences in 
lipoprotein levels in MD susceptible and resistant lines.  
 
Second, we demonstrated changes in lipoprotein levels induced by MDV infection in 
MD susceptible and resistant chicken lines. Although total cholesterol and HDL 
cholesterol displayed no changes before and after MDV infection in both lines, we 
found that the (LDL+VLDL) level was inversely regulated in the two lines in 
response to MDV infection: (LDL+VLDL) was slightly elevated in the MD 
susceptible line while it was slightly reduced in the MD resistant line. The slight 
increase of (LDL+VLDL) level in MD susceptible chickens after MDV infection may 
provide a clue for MDV induced atherosclerosis as LDL is a main risk factor for 
atherosclerosis. 
 
At this time, we cannot identify which mechanisms are responsible for the differences 
in lipoprotein metabolism induced by MDV infection in MD susceptible and resistant 
line. Regardless, increased (LDL+VLDL) cholesterol levels, primarily LDL 
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cholesterol, may be very important in the pathogenesis of MDV induced 
atherosclerosis. Results of experiments by other investigators also suggest that 
herpesvirus infection enhanced LDL binding and uptake in addition to transcription 
of the LDL receptor gene
142
. Fabricant et al. mentioned one mechanism that may be 
involved in cholesterol accumulation induced by MDV infection: MDV may enhance 
uptake of LDL via a LDL receptor mediated pathway
143
. However, the precise role of 
LDL in cholesterol accumulation following MDV infection remains to be resolved. 
 
In conclusion, the results of our experiments support the hypothesis that different 
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